The visionary biotech entrepreneur: Arun Asaithambi’s journey from PhD to NASDAQ
The company’s remarkable journey included an IPO in 2020, raising over $100 million in total funding.
The company’s remarkable journey included an IPO in 2020, raising over $100 million in total funding.
The innovation segment is dominated by pharma services (CDMO, CRO, pharma IT) and health-tech with vaccines and biotech, and med-tech emerging as green shoots
The two medicines prescribed together is a standard treatment regimen approved in over 100 countries for both early and metastatic HER2-positive breast cancer.
Resurgence of interest and new technologies bring a huge opportunity for the vaccine development field, says Biocon CMD Kiran Mazumdar-Shaw.
Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
Average deal size decreased to $19 million, from $178 million recorded in the previous month.
The inability of analysts to fully understand biotech companies is keeping the value of Kiran Mazumdar-Shaw’s company down.